ClinicalTrials.gg
CompletedNCT00385736Updated Apr 11, 2011Results posted

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

A Phase 3 interventional study of adalimumab and adalimumab in Ulcerative Colitis, sponsored by Abbott. Completed at 80 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.

Enrollment
3rd of 18
576 · median 152
Started
2006
with 2 others
Phase 3
10 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
2 of 18
Abbott

Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 3 that started in 2006, is one of 10 in phase 3, and was the 1st registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing adalimumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.

Read the detailed description

This was a Phase 3, multicenter, randomized, double-blind (DB), placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-TNF monoclonal antibody adalimumab for the induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).

Adult participants with moderate to severe UC (Mayo score of 6 to 12 points with endoscopy subscore of 2 to 3 points), confirmed by colonoscopy with biopsy or by flexible sigmoidoscopy with biopsy, were enrolled at 80 sites worldwide. The study enrolled 576 participants, including 186 participants under the original protocol and protocol Amendments 1 and 2, and 390 participants under protocol Amendments 3 and 4.

Participants enrolled in the study prior to Amendment 3 were randomized in a 1:1 ratio to receive adalimumab or placebo during the 12-week DB induction period. Participants received 4 injections of adalimumab 40 mg (160 mg) or 4 injections of placebo at Baseline (Week 0), followed by 2 injections of adalimumab 40 mg (80 mg) or 2 injections of placebo at Week 2, followed by 1 injection of adalimumab 40 mg or placebo at Weeks 4 and 6. At Week 8, participants randomized to placebo received 4 injections of adalimumab 40 mg (160 mg) followed by 2 injections of adalimumab 40 mg (80 mg) at Week 10. Participants randomized to adalimumab received 3 injections of placebo and 1 injection of adalimumab 40 mg at Week 8 and 1 injection of placebo and 1 injection of adalimumab 40 mg at Week 10. All participants continued to receive 1 injection of open-label (OL) adalimumab 40 mg every other week beginning at Week 12 up to Week 52 (or the early termination visit). Starting at Week 14, participants who had inadequate responses to treatment (as defined using partial Mayo scores) were permitted to dose escalate to adalimumab 40 mg weekly. Participants with persistent inadequate response while on weekly treatment could be discontinued from the study at the discretion of the investigator.

In August 2007, the study design was amended to incorporate an additional adalimumab induction dosing arm of 80/40 mg. Earlier that year, both 160/80-mg and 80/40-mg induction regimens had been approved in the EU as induction treatment for Crohn's disease. The adalimumab induction dosing regimen of 80/40 mg was therefore included so that both of these approved induction regimens would be evaluated for the induction of remission of UC.

Participants enrolled in the study after Amendment 3 were randomized in a 1:1:1 ratio to receive adalimumab (1 of 2 regimens) or placebo during the 8-week DB induction period. Participants received DB therapy from Baseline until Week 8 and OL therapy from Week 8 until the end of the study. In the first adalimumab dosing arm (adalimumab 80/40), participants received 2 injections of adalimumab 40 mg (80 mg) and 2 injections of placebo at Baseline followed by 1 injection of adalimumab 40 mg and 1 injection of placebo at Week 2, and 1 injection of adalimumab 40 mg every other week thereafter. In the second adalimumab DB induction dosing arm (adalimumab 160/80), participants received 4 injections of adalimumab 40 mg (160 mg) at Baseline followed by 2 injections of adalimumab 40 mg (80 mg) at Week 2, and 1 injection of adalimumab 40 mg every other week thereafter. Participants randomized to placebo received 4 injections of placebo at Baseline followed by 2 injections of placebo at Week 2, and 1 injection of placebo at Weeks 4 and 6. Beginning at Week 8, but after the Week 8 study assessments had been completed, all participants received 1 injection of OL adalimumab 40 mg every other week until Week 52 or early termination. Starting at Week 12, participants who had inadequate responses to treatment (as defined using partial Mayo scores) were permitted to dose escalate to adalimumab 40 mg weekly. Participants with persistent inadequate response while on weekly treatment could be discontinued from the study at the discretion of the investigator.

For the analysis of efficacy parameters during the DB Period through Week 8, only participants randomized under Protocol Amendment 3 or later were considered ("Efficacy Analysis Set - Induction" in the participant flow). For the analysis of efficacy parameters during the OL Period through Week 52, all randomized participants (under any version of the protocol) who received at least 1 dose of study drug were considered ("Efficacy Analysis Set - Maintenance" in the participant flow). For the analysis of safety parameters, all participants who received at least 1 dose of study drug were considered ("Safety Analysis Set" in the participant flow).

Twelve ranked secondary variables during the DB Period through Week 8 were to be tested in a hierarchical order to account for multiple testing. These variables are identified as "Ranked Secondary Endpoints" in the results section below. Additionally, non-ranked secondary variables during the OL Period through Week 52 were tested and are presented after the ranked secondary endpoints in the results section below.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Moderate to Severe Ulcerative Colitis
  • Double-blind
  • Adalimumab
  • Induction of Clinical Remission
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The following eligibility criteria applied to participants enrolled following Amendment 3 to the study protocol.

Inclusion criteria

Inclusion Criteria:

  1. Male and female participants >= 18 years of age
  2. Diagnosis of ulcerative colitis for greater than 90 days prior to Baseline
  3. Diagnosis of active ulcerative colitis confirmed by colonoscopy with or flexible sigmoidoscopy with biopsy during the Screening Period, with exclusion of infection
  4. Active UC with a Mayo score of 6 to 12 points and endoscopy subscore of 2 to 3 points, despite concurrent treatment with at least 1 of the following (oral or or both as defined below):

    • Stable oral corticosteroid dose (prednisone dose of >= 20 mg/day or equivalent) for at least 14 days prior to Baseline or stable oral corticosteroid dose (prednisone of \< 20 mg/day) for at least 40 days prior to Baseline.

    and/or

    • At least a consecutive 90 day course of azathioprine or 6-mercaptopurine (6 MP) prior to Baseline, with a dose of azathioprine >= 1.5 mg/kg/day or 6 MP >= 1 mg/kg/day (rounded to the nearest available tablet formulation), or a dose that is the highest tolerated by the participant (e.g., due to leukopenia, elevated liver enzymes, nausea) during that time. Participant was to be on a stable dose for at least 28 days prior to Baseline.

    Concurrent therapy was not required for participants who were previously treated with corticosteroids or immunosuppressants (azathioprine or 6-MP) during the previous 5 years and, in the judgment of the investigator, have failed to respond to or could not tolerate their treatment.

  5. Had to be able to self-administer or has caregiver who can reliably administer subcutaneous injections.
  6. Had to be able and willing to give written and to comply with the requirements of this study protocol.
  7. Female had to be either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or of childbearing potential and practicing an approved method of throughout the study and for 150 days after last dose of study drug. Examples of approved methods of birth control included the following:

    • Condoms, sponge, foams, jellies, diaphragm or intrauterine device
    • Oral, parenteral or intravaginal contraceptives for 90 days prior to study drug administration
    • A vasectomized partner
  8. The results of the serum pregnancy test performed at the Screening Visit and urine pregnancy test performed at the Baseline Visit had to be negative.
  9. Judged to be in generally good health as determined by the principal investigator

Exclusion criteria

Exclusion Criteria:

  1. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for ulcerative colitis or is planning bowel surgery.
  2. Received infliximab or any other anti-TNF agent or any biological therapy in the past.
  3. Received previous treatment with adalimumab or previous participation in an adalimumab clinical study.
  4. Received cyclosporine, tacrolimus, or mycophenolate mofetil within 30 days prior to Baseline.
  5. Received intravenous within 14 days prior to Screening or during the Screening Period.
  6. Received therapeutic enema or suppository, other than required for endoscopy, within 14 days prior to the Screening endoscopy and during the remainder of the Screening Period.
  7. Current diagnosis of fulminant colitis and/or toxic megacolon.
  8. Participants with disease limited to the rectum (ulcerative proctitis).
  9. Current diagnosis of indeterminate colitis.
  10. Current diagnosis and/or history of Crohn's disease.
  11. Currently receiving total parenteral nutrition.
  12. Discontinued use of azathioprine or 6-MP within 28 days of Baseline.
  13. Discontinued use of corticosteroid within 14 days of Baseline.
  14. Participants using aminosalicylates for less than 90 days prior to Baseline, not on a stable dose for at least 28 days prior to Baseline, or discontinued use within 28 days of Baseline.
  15. Participants with positive Clostridium difficile stool assay.
  16. Infections requiring treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to Baseline or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to Baseline.
  17. History of other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix. If the Screening colonoscopy/flexible sigmoidoscopy showed evidence of dysplasia or a malignancy, the participant was not to be enrolled in the study.
  18. History of listeria, histoplasmosis, chronic or active infection, , immunodeficiency syndrome, central nervous system demyelinating disease, or untreated tuberculosis (TB).
  19. Female participants who was pregnant or breast-feeding or considering becoming pregnant during the study. There should be at least a 150-day period between the last dose of study drug and either conception or initiation of breast-feeding in women of .
  20. Poorly controlled medical condition(s), such as uncontrolled diabetes, unstable ischemic heart disease, moderate to severe congestive heart failure, recent cerebrovascular accident and any other condition, which in the opinion of the investigator, would put the participant at risk by participation in the protocol.
  21. Received any agent within 30 days or 5 half lives prior to Baseline (whichever is longer).
  22. History of drug or alcohol abuse during the previous year.
  23. Participants with known to the of adalimumab as stated in the label.
  24. Participants with any prior exposure to Tysabri® (natalizumab).
  25. Participants currently taking both budesonide and prednisone (or equivalent) simultaneously.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
576 participants (actual)

Study arms

  • Experimental
    Adalimumab 80/40

    Biological: adalimumab

  • Experimental
    Adalimumab 160/80/40

    Biological: adalimumab

  • Placebo comparator
    Placebo

    Biological: placebo

Interventions

  • Biologicaladalimumab

    Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.

    Also known as: ABT-D2E7, Humira

  • Biologicaladalimumab

    Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo

    Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Clinical Remission Per Mayo Score at Week 8

    Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8

Secondary outcomes

  1. Ranked Secondary Endpoint #1: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 160/80/40 Versus Placebo).

    Clinical response per Mayo score is defined as a decrease in Mayo score of \>= 3 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8

  2. Ranked Secondary Endpoint #2: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 160/80/40 Versus Placebo).

    Mucosal healing is defined as Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)

    Time frame: Week 8

  3. Ranked Secondary Endpoint #3: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).

    Rectal Bleeding Subscore ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

    Time frame: Week 8

  4. Ranked Secondary Endpoint #4: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).

    The Physician's Global Assessment Subscore acknowledges the 3 other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the subject's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the subject's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)

    Time frame: Week 8

  5. Ranked Secondary Endpoint #5: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).

    Stool Frequency Subscore ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal

    Time frame: Week 8

  6. Ranked Secondary Endpoint #6: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 80/40 Versus Placebo).

    Clinical response per Mayo score is defined as a decrease in Mayo score of \>= 3 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 8

  7. Ranked Secondary Endpoint #7: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 80/40 Versus Placebo).

    Mucosal healing defined as Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)

    Time frame: Week 8

  8. Ranked Secondary Endpoint #8: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).

    Rectal Bleeding Subscore ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

    Time frame: Week 8

  9. Ranked Secondary Endpoint #9: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).

    The Physician's Global Assessment Subscore acknowledges the 3 other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the subject's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the subject's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)

    Time frame: Week 8

  10. Ranked Secondary Endpoint #10: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).

    Stool Frequency Subscore ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal

    Time frame: Week 8

  11. Ranked Secondary Endpoint #11: Proportion of IBDQ Responders at Week 8 (Adalimumab 160/80/40 Versus Placebo).

    Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) defined as a \>= 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Week 8

  12. Ranked Secondary Endpoint #12: Proportion of IBDQ Responders at Week 8 (Adalimumab 80/40 Versus Placebo).

    Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) defined as a \>= 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

    Time frame: Week 8

  13. Proportion of Participants With Clinical Remission Per Mayo Score at Week 52

    Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

  14. Proportion of Participants With Clinical Remission Per Partial Mayo Score at Week 52

    Clinical remission per partial Mayo score is defined as a partial Mayo score \<= 2 and no individual subscore \> 1. The partial Mayo score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

  15. Proportion of Participants With Clinical Response Per Mayo Score at Week 52

    Clinical response per Mayo score is defined as a decrease in Mayo score of \>= 3 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

  16. Proportion of Participants With Clinical Response Per Partial Mayo Score at Week 52

    Clinical response per partial Mayo score is defined as a decrease in partial Mayo score of \>= 2 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The partial Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

  17. Proportion of Participants With Mucosal Healing at Week 52

    Mucosal healing is defined as Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)

    Time frame: Week 52

  18. Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 52

    Rectal Bleeding Subscore ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

    Time frame: Week 52

  19. Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 52

    The Physician's Global Assessment Subscore acknowledges the 3 other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the subject's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the subject's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)

    Time frame: Week 52

  20. Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 52

    Stool Frequency Subscore ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal

    Time frame: Week 52

  21. Proportion of Participants With Clinical Remission Per Mayo Score at Week 52 Among Participants Who Were Systemic Corticosteroid-free at Week 52

    Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

    Time frame: Week 52

07

Results

Posted May 27, 2010

Participant flow

Efficacy Analysis Set - Induction
Participant flow — Efficacy Analysis Set - Induction
MilestonePlaceboAdalimumab 80/40Adalimumab 160/80/40
Started130130130
Completed121118121
Not completed9129
Withdrew: Adverse event564
Withdrew: Withdrawal by subject021
Withdrew: Lost to follow-up020
Withdrew: Lack of efficacy421
Withdrew: Protocol violation002
Withdrew: Other001
Efficacy Analysis Set - Maintenance
Participant flow — Efficacy Analysis Set - Maintenance
MilestonePlaceboAdalimumab 80/40Adalimumab 160/80/40
Started222130223
Completed15386143
Not completed694480
Withdrew: Adverse event231523
Withdrew: Withdrawal by subject6614
Withdrew: Lost to follow-up022
Withdrew: Lack of efficacy381631
Withdrew: Protocol violation216
Withdrew: Other044
Safety Analysis Set
Participant flow — Safety Analysis Set
MilestonePlaceboAdalimumab 80/40Adalimumab 160/80/40
Started223130223
Completed15386143
Not completed704480
Withdrew: Adverse event231523
Withdrew: Withdrawal by subject6614
Withdrew: Lost to follow-up022
Withdrew: Lack of efficacy381631
Withdrew: Protocol violation216
Withdrew: Other144

Outcome measures

PrimaryProportion of Participants With Clinical Remission Per Mayo Score at Week 8

Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Proportion of Participants With Clinical Remission Per Mayo Score at Week 8
Proportion of participantsPlaceboAdalimumab 80/40Adalimumab 160/80/40
Proportion of Participants With Clinical Remission Per Mayo Score at Week 89.210.018.5
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.031 (The primary endpoint analysis was carried out in hierarchical order (as presented) to handle the multiplicity issues induced by the two adalimumab groups being compared to placebo and to control the overall alpha level of 0.05.)
  • Placebo vs Adalimumab 80/40 · Chi-squared · p = 0.833 (The primary endpoint analysis was carried out in hierarchical order (as presented) to handle the multiplicity issues induced by the two adalimumab groups being compared to placebo and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #1: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 160/80/40 Versus Placebo).

Clinical response per Mayo score is defined as a decrease in Mayo score of \>= 3 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #1: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 160/80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 160/80/40
Ranked Secondary Endpoint #1: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 160/80/40 Versus Placebo).44.654.6
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.107 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #2: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 160/80/40 Versus Placebo).

Mucosal healing is defined as Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #2: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 160/80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 160/80/40
Ranked Secondary Endpoint #2: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 160/80/40 Versus Placebo).41.546.9
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.382 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #3: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).

Rectal Bleeding Subscore ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #3: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 160/80/40
Ranked Secondary Endpoint #3: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).66.277.7
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.038 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #4: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).

The Physician's Global Assessment Subscore acknowledges the 3 other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the subject's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the subject's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #4: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 160/80/40
Ranked Secondary Endpoint #4: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).46.960.0
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.035 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #5: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).

Stool Frequency Subscore ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #5: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 160/80/40
Ranked Secondary Endpoint #5: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 160/80/40 Versus Placebo).37.748.5
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.080 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #6: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 80/40 Versus Placebo).

Clinical response per Mayo score is defined as a decrease in Mayo score of \>= 3 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #6: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 80/40
Ranked Secondary Endpoint #6: Proportion of Participants With Clinical Response Per Mayo Score at Week 8 (Adalimumab 80/40 Versus Placebo).44.651.5
Statistical analysis
  • Placebo vs Adalimumab 80/40 · Chi-squared · p = 0.264 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #7: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 80/40 Versus Placebo).

Mucosal healing defined as Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #7: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 80/40
Ranked Secondary Endpoint #7: Proportion of Participants With Mucosal Healing at Week 8 (Adalimumab 80/40 Versus Placebo).41.537.7
Statistical analysis
  • Placebo vs Adalimumab 80/40 · Chi-squared · p = 0.526 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #8: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).

Rectal Bleeding Subscore ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #8: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 80/40
Ranked Secondary Endpoint #8: Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).66.270.0
Statistical analysis
  • Placebo vs Adalimumab 80/40 · Chi-squared · p = 0.506 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #9: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).

The Physician's Global Assessment Subscore acknowledges the 3 other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the subject's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the subject's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #9: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 80/40
Ranked Secondary Endpoint #9: Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).46.953.8
Statistical analysis
  • Placebo · Chi-squared · p = 0.264 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #10: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).

Stool Frequency Subscore ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #10: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 80/40
Ranked Secondary Endpoint #10: Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 8 (Adalimumab 80/40 Versus Placebo).37.736.2
Statistical analysis
  • Placebo vs Adalimumab 80/40 · Chi-squared · p = 0.797 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #11: Proportion of IBDQ Responders at Week 8 (Adalimumab 160/80/40 Versus Placebo).

Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) defined as a \>= 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #11: Proportion of IBDQ Responders at Week 8 (Adalimumab 160/80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 160/80/40
Ranked Secondary Endpoint #11: Proportion of IBDQ Responders at Week 8 (Adalimumab 160/80/40 Versus Placebo).57.760.8
Statistical analysis
  • Placebo vs Adalimumab 160/80/40 · Chi-squared · p = 0.614 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryRanked Secondary Endpoint #12: Proportion of IBDQ Responders at Week 8 (Adalimumab 80/40 Versus Placebo).

Response per the Inflammatory Bowel Disease Questionnaire (IBDQ) defined as a \>= 16-point increase from Baseline in total IBDQ score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

Time frame:
Week 8
Reported as:
Number · Proportion of participants
Ranked Secondary Endpoint #12: Proportion of IBDQ Responders at Week 8 (Adalimumab 80/40 Versus Placebo).
Proportion of participantsPlaceboAdalimumab 80/40
Ranked Secondary Endpoint #12: Proportion of IBDQ Responders at Week 8 (Adalimumab 80/40 Versus Placebo).57.753.8
Statistical analysis
  • Placebo vs Adalimumab 80/40 · Chi-squared · p = 0.532 (Ranked secondary analyses were carried out in hierarchical order (as presented) to handle the multiplicity issues and to control the overall alpha level of 0.05.)
SecondaryProportion of Participants With Clinical Remission Per Mayo Score at Week 52

Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Clinical Remission Per Mayo Score at Week 52
Proportion of participantsTotal
Proportion of Participants With Clinical Remission Per Mayo Score at Week 5224.2
SecondaryProportion of Participants With Clinical Remission Per Partial Mayo Score at Week 52

Clinical remission per partial Mayo score is defined as a partial Mayo score \<= 2 and no individual subscore \> 1. The partial Mayo score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Clinical Remission Per Partial Mayo Score at Week 52
Proportion of participantsTotal
Proportion of Participants With Clinical Remission Per Partial Mayo Score at Week 5228.3
SecondaryProportion of Participants With Clinical Response Per Mayo Score at Week 52

Clinical response per Mayo score is defined as a decrease in Mayo score of \>= 3 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Clinical Response Per Mayo Score at Week 52
Proportion of participantsTotal
Proportion of Participants With Clinical Response Per Mayo Score at Week 5242.6
SecondaryProportion of Participants With Clinical Response Per Partial Mayo Score at Week 52

Clinical response per partial Mayo score is defined as a decrease in partial Mayo score of \>= 2 points and \>= 30% from Baseline, plus either a decrease in rectal bleeding subscore of \>= 1 point or an absolute rectal bleeding subscore of 0 or 1. The partial Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Clinical Response Per Partial Mayo Score at Week 52
Proportion of participantsTotal
Proportion of Participants With Clinical Response Per Partial Mayo Score at Week 5241.6
SecondaryProportion of Participants With Mucosal Healing at Week 52

Mucosal healing is defined as Endoscopy Subscore of 0 or 1 as assessed by flexible sigmoidoscopy. Possible scores range from 0-3 as follows: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration)

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Mucosal Healing at Week 52
Proportion of participantsTotal
Proportion of Participants With Mucosal Healing at Week 5236.5
SecondaryProportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 52

Rectal Bleeding Subscore ranges from 0-3 as follows: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 52
Proportion of participantsTotal
Proportion of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (<= 1) at Week 5247.0
SecondaryProportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 52

The Physician's Global Assessment Subscore acknowledges the 3 other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the subject's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the subject's performance status. Possible scores range from 0-3 as follows: 0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3)

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 52
Proportion of participantsTotal
Proportion of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (<= 1) at Week 5241.7
SecondaryProportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 52

Stool Frequency Subscore ranges from 0-3 as follows: 0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 52
Proportion of participantsTotal
Proportion of Participants With Stool Frequency Subscore Indicative of Mild Disease (<= 1) at Week 5236.5
SecondaryProportion of Participants With Clinical Remission Per Mayo Score at Week 52 Among Participants Who Were Systemic Corticosteroid-free at Week 52

Clinical remission per Mayo score is defined as a total Mayo score \<= 2 and no individual subscore \> 1. The Mayo Score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 12 (severe disease) and is a composite of 4 subscores: Stool Frequency Subscore, Rectal Bleeding Subscore, Endoscopy Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Time frame:
Week 52
Reported as:
Number · Proportion of participants
Proportion of Participants With Clinical Remission Per Mayo Score at Week 52 Among Participants Who Were Systemic Corticosteroid-free at Week 52
Proportion of participantsTotal
Proportion of Participants With Clinical Remission Per Mayo Score at Week 52 Among Participants Who Were Systemic Corticosteroid-free at Week 5241.5

Adverse events

Collected over Adverse event data are presented through Week 8 for the placebo, adalimumab 80/40, and adalimumab 160/80/40 groups. Adverse event data are presented through Week 52 for the Any Adalimumab group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—17/223 (7.6%)34/223 (15.2%)
Adalimumab 80/40—5/130 (3.8%)30/130 (23.1%)
Adalimumab 160/80/40—9/223 (4%)34/223 (15.2%)
Any Adalimumab—76/557 (13.6%)210/557 (37.7%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventPlaceboAdalimumab 80/40Adalimumab 160/80/40Any Adalimumab
Colitis ulcerativeGastrointestinal disorders13/2233/1304/22334/557
Abscess ruptureInfections and infestations0/2231/1300/2231/557
Perirectal abscessInfections and infestations0/2231/1300/2232/557
Deep vein thrombosisVascular disorders0/2230/1300/2233/557
Coronary artery diseaseCardiac disorders0/2230/1301/2231/557
ColitisGastrointestinal disorders1/2230/1300/2231/557
PneumoniaInfections and infestations1/2230/1300/2232/557
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2230/1300/2231/557
SyncopeNervous system disorders0/2230/1301/2231/557
Personality disorderPsychiatric disorders0/2230/1301/2231/557
Most frequent other events
Most frequent other events
EventPlaceboAdalimumab 80/40Adalimumab 160/80/40Any Adalimumab
Colitis ulcerativeGastrointestinal disorders8/2237/1309/22385/557
NasopharyngitisInfections and infestations4/2236/1306/22353/557
HeadacheNervous system disorders16/2239/1307/22347/557
ArthralgiaMusculoskeletal and connective tissue disorders1/2235/1304/22343/557
Upper respiratory tract infectionInfections and infestations6/2236/1303/22337/557
FatigueGeneral disorders5/2232/1309/22333/557
NauseaGastrointestinal disorders4/2234/1304/22331/557

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboAdalimumab 80/40Adalimumab 160/80/40Total
<=18 years1214
Between 18 and 65 years125120124369
>=65 years48517
Age Continuous
Age Continuous(years)PlaceboAdalimumab 80/40Adalimumab 160/80/40Total
Mean38.9 ± 12.6841.6 ± 13.9938.2 ± 13.4639.5 ± 13.43
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab 80/40Adalimumab 160/80/40Total
Female485247147
Male827883243
Region of Enrollment
Region of Enrollment(participants)PlaceboAdalimumab 80/40Adalimumab 160/80/40Total
United States323041103
Slovakia12221347
Austria711523
Italy116724
Czech Republic23111852
Hungary93719
Canada26252071
Belgium4228
Poland2226
Germany314926
Netherlands1405
Sweden0066
08

Study locations

80 sites
  • Site Ref # / Investigator 2080
    Birmingham, Alabama 35209, United States
  • Site Ref # / Investigator 6034
    Mobile, Alabama 36617, United States
  • Site Ref # / Investigator 5100
    Fayetteville, Arkansas 72703, United States
  • Site Ref # / Investigator 5390
    Orange, California 92868, United States
  • Site Ref # / Investigator 5392
    San Diego, California 92123, United States
  • Site Ref # / Investigator 2245
    Bridgeport, Connecticut 06606, United States
  • Site Ref # / Investigator 2240
    Gainesville, Florida 32610, United States
  • Site Ref # / Investigator 2230
    South Miami, Florida 33143, United States
  • Site Ref # / Investigator 5393
    Atlanta, Georgia 30308, United States
  • Site Ref # / Investigator 2231
    Atlanta, Georgia 30342, United States
  • Site Ref # / Investigator 2498
    Chicago, Illinois 60637, United States
  • Site Ref # / Investigator 2078
    Chevy Chase, Maryland 20815, United States
  • Site Ref # / Investigator 2238
    Silver Springs, Maryland 20901, United States
  • Site Ref # / Investigator 1971
    Boston, Massachusetts 02114, United States
  • Site Ref # / Investigator 2246
    Rochester, Minnesota 55905, United States
  • Site Ref # / Investigator 2243
    Kansas City, Missouri 64131, United States
  • Site Ref # / Investigator 2247
    Mexico, Missouri 65265, United States
  • Site Ref # / Investigator 2233
    Lincoln, Nebraska 68503, United States
  • Site Ref # / Investigator 2236
    Cedar Knolls, New Jersey 07927, United States
  • Site Ref # / Investigator 2072
    New York, New York 10028, United States
  • Site Ref # / Investigator 2241
    Charlotte, North Carolina 28211, United States
  • Site Ref # / Investigator 2232
    Raleigh, North Carolina 27612, United States
  • Site Ref # / Investigator 11801
    Wilmington, North Carolina 28403, United States
  • Site Ref # / Investigator 2074
    Cincinnati, Ohio 45219, United States
  • Site Ref # / Investigator 2126
    Cleveland, Ohio 44106-5066, United States
  • Site Ref # / Investigator 6090
    Germantown, Tennessee 38138, United States
  • Site Ref # / Investigator 2076
    Nashville, Tennessee 37203, United States
  • Site Ref # / Investigator 2229
    Bellevue, Washington 98004, United States
  • Site Ref # / Investigator 2077
    Milwaukee, Wisconsin 53215, United States
  • Site Ref # / Investigator 4936
    Graz, 8036, Austria
  • Site Ref # / Investigator 6224
    Hall, 6060, Austria
  • Site Ref # / Investigator 3830
    Innsbruck, A-6020, Austria
  • Site Ref # / Investigator 7508
    Linz, A-4010, Austria
  • Site Ref # / Investigator 3829
    Salzburg, A-5020, Austria
  • Site Ref # / Investigator 4937
    Vienna, 1030, Austria
  • Site Ref # / Investigator 3831
    Vienna, 1090, Austria
  • Site Ref # / Investigator 3861
    Bonheiden, 2820, Belgium
  • Site Ref # / Investigator 3859
    Liege, 4000, Belgium
  • Site Ref # / Investigator 3862
    Roeselare, 8800, Belgium
  • Site Ref # / Investigator 2224
    Calgary, Alberta T2N 4Z6, Canada
  • Site Ref # / Investigator 2227
    Edmonton, Alberta T6G 2X8, Canada
  • Site Ref # / Investigator 2226
    Vancouver, British Columbia V6Z-2K5, Canada
  • Site Ref # / Investigator 2223
    Winnipeg, Manitoba R3A 1R9, Canada
  • Site Ref # / Investigator 2138
    Toronto, Ontario M3N 2V7, Canada
  • Site Ref # / Investigator 3858
    Brno, 62500, Czech Republic
  • Site Ref # / Investigator 3856
    Olomouc, 77520, Czech Republic
  • Site Ref # / Investigator 3857
    Ostrava, 708 52, Czech Republic
  • Site Ref # / Investigator 3854
    Prague 1, 118 83, Czech Republic
  • Site Ref # / Investigator 3855
    Prague 7, 17000, Czech Republic
  • Site Ref # / Investigator 3832
    Berlin, 13353, Germany
  • Site Ref # / Investigator 13983
    Essen, D-45239, Germany
  • Site Ref # / Investigator 3834
    Jena, 07747, Germany
  • Site Ref # / Investigator 3833
    Kiel, 24105, Germany
  • Site Ref # / Investigator 3878
    Mainz, 55131, Germany
  • Site Ref # / Investigator 3897
    Munich, 81377, Germany
  • Site Ref # / Investigator 3852
    Budapest, H-1076, Hungary
  • Site Ref # / Investigator 3850
    Budapest, H-1125, Hungary
  • Site Ref # / Investigator 3849
    Gyor, H-9024, Hungary
  • Site Ref # / Investigator 3876
    Bologna, 40138, Italy
  • Site Ref # / Investigator 3848
    Milan, 20157, Italy
  • Site Ref # / Investigator 3845
    Palermo, 90146, Italy
  • Site Ref # / Investigator 6232
    Rome, 00133, Italy
  • Site Ref # / Investigator 3846
    Rome, 00152, Italy
  • Site Ref # / Investigator 3873
    Eindhoven, 5623 EJ, Netherlands
  • Site Ref # / Investigator 3875
    Leiden, 2333 ZA, Netherlands
  • Site Ref # / Investigator 8061
    Lodz, 90-153, Poland
  • Site Ref # / Investigator 13804
    Sopot, 81-756, Poland
  • Site Ref # / Investigator 8055
    Warsaw, 02-507, Poland
  • Site Ref # / Investigator 2392
    Ponce, 00717, Puerto Rico
  • Site Ref # / Investigator 2393
    San Juan, 00936-5067, Puerto Rico
  • Site Ref # / Investigator 3839
    Banska Bystrica, 97 401, Slovakia
  • Site Ref # / Investigator 3838
    Bratislava, 811 07, Slovakia
  • Site Ref # / Investigator 3841
    Bratislava, 833 05, Slovakia
  • Site Ref # / Investigator 3842
    Nitra, 94 901, Slovakia
  • Site Ref # / Investigator 14721
    Presov, 08001, Slovakia
  • Site Ref # / Investigator 14521
    Trencin, 91101, Slovakia
  • Site Ref # / Investigator 3840
    Trnava, 917 01, Slovakia
  • Site Ref # / Investigator 8503
    Gothenburg, 41345, Sweden
  • Site Ref # / Investigator 8504
    Linkoping, 581 85, Sweden
  • Site Ref # / Investigator 8502
    Lund, 22185, Sweden
09

References and documents

Publications

  • Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, Hendrickson BA. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018 Jun;19(3):437-447. doi: 10.1007/s40257-017-0341-6. PubMed 29380251 ↗
  • Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan;146(1):110-118.e3. doi: 10.1053/j.gastro.2013.09.032. Epub 2013 Sep 22. PubMed 24067881 ↗
  • Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul;19(8):1700-9. doi: 10.1097/MIB.0b013e318281f2b7. PubMed 23665965 ↗
  • Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780-7. doi: 10.1136/gut.2010.221127. Epub 2011 Jan 5. PubMed 21209123 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Apr 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2006
First posted
Oct 11, 2006
Start
Nov 2006
Primary completionActual
Apr 2009
CompletionActual
Mar 2010
Results first posted
May 27, 2010
Last update
Apr 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00385736
Lead sponsor
Abbott
First posted
Oct 11, 2006
Start date
Nov 2006
Primary completion
Apr 2009
Completion
Mar 2010
Results posted
May 27, 2010
Last update
Apr 11, 2011

Study contacts

Roopal Thakkar, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion